Evidence map›Paper›PMID 37455900›Full record

ReviewFrontiers in endocrinology2023

Energy expenditure in myelofibrosis patients treated with a JAK1/2 inhibitor.

Douglas Tremblay, Mikaela Dougherty, John Mascarenhas, Emily Jane Gallagher

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Douglas TremblayTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Mikaela DoughertyTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
John MascarenhasTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Emily Jane GallagherDivision of Endocrinology, Diabetes, and Bone Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Icahn School of Medicine at Mount Sinai · US

Funding

Conduits: Mount Sinai Health System Translational Science HubUL1TR004419 · NCATS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Rosalind J Wright · 2022 to 2026
$46.4M
Understanding how elevated triglycerides contribute to triple negative breast cancer growth and metastasisR37CA266853 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Emily Jane Gallagher · 2022 to 2026
$2.5M
NCATS NIH HHS UL1 TR004419NCI NIH HHS R37 CA266853
6 · The paper itself

Abstract

Weight gain is a known adverse effect of ruxolitinib, a JAK1/2 inhibitor that is the mainstay of treatment for many patients with myelofibrosis. The mechanisms behind weight increase with ruxolitinib is incompletely understood, although decreased adipose tissue lipolysis and increased appetite due to blocking the effects of leptin in the hypothalamus have been proposed. In order to explore the metabolic changes in ruxolitinib-treated patients with myelofibrosis, we performed a pilot study to assess the feasibility of using a portable indirect calorimeter to quantify energy expenditure before and during ruxolitinib treatment and report the results of two patients. Waist circumference increased during ruxolitinib treatment in both patients. Energy expenditure initially increased followed by a decrease and then increase again, but to levels below baseline. These results suggest that weight gain secondary to ruxolitinib may be related to changes in whole body energy expenditure.

Indexed as

Primary MyelofibrosisEnergy MetabolismHumansJanus Kinase 1NitrilesPilot ProjectsPyrazolesPyrimidinesWeight GainJAK1 protein, humanJanus Kinase 1NitrilesPyrazolesPyrimidinesruxolitinibenergy expenditureintoleranceleptinruxolitinibweight gain

Identifiers

PMID37455900
PMCPMC10339379
OpenAlexW4382725559

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.